title: Atorvastatin protects against cerebral infarction via inhibition of NADPH oxidase-derived superoxide in ischemic stroke.
abstract: Statins have recently been shown to exert neuronal protection in ischemic stroke. Reactive oxygen species, specifically superoxide formed during the early phase of reperfusion, augment neuronal injury. NADPH oxidase is a key enzyme for superoxide production. The present study tested the hypothesis that atorvastatin protects against cerebral infarction via inhibition of NADPH oxidase-derived superoxide in transient focal ischemia. Transient focal ischemia was created in halothane-anesthetized adult male Sprague-Dawley rats (250-300 g) by middle cerebral artery occlusion (MCAO). Atorvastatin (Lipitor, 10 mg/kg sc) was administered three times before MCAO. Infarct volume was measured by triphenyltetrazolium chloride staining. NADPH oxidase enzymatic activity and superoxide levels were quantified in the ischemic core and penumbral regions by lucigenin (5 microM)-enhanced chemiluminescence. Expression of NADPH oxidase membrane subunit gp91(phox) and membrane-translocated subunit p47(phox) and small GTPase Rac-1 was analyzed by Western blot. NADPH oxidase activity and superoxide levels increased after reperfusion and peaked within 2 h of reperfusion in the penumbra, but not in the ischemic core, in MCAO rats. Atorvastatin pretreatment prevented these increases, blunted expression of membrane subunit gp91(phox), and prevented translocation of cytoplasmic subunit p47(phox) to the membrane in the penumbra 2 h after reperfusion. Consequently, cerebral infarct volume was significantly reduced in atorvastatin-treated compared with nontreated MCAO rats 24 h after reperfusion. These results indicate that atorvastatin protects against cerebral infarction via inhibition of NADPH oxidase-derived superoxide in transient focal ischemia.
authors.affiliation: Depts. of Pharmacology and Neurology, B403 Life Sciences Bldg., Michigan State Univ., East Lansing, MI 48824-1317, USA.
authors.forename: Hua
authors.initials: H
authors.lastname: Hong
authors.forename: Jin-Sheng
authors.initials: JS
authors.lastname: Zeng
authors.forename: David L
authors.initials: DL
authors.lastname: Kreulen
authors.forename: David I
authors.initials: DI
authors.lastname: Kaufman
authors.forename: Alex F
authors.initials: AF
authors.lastname: Chen
mesh_terms: D000818:Animals; D000069059:Atorvastatin; D002544:Cerebral Infarction / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control*; D004195:Disease Models, Animal; D006538:Heptanoic Acids / Q000494:pharmacology*; D008297:Male; D019255:NADPH Oxidases / Q000032:analysis / Q000235:genetics / Q000378:metabolism*; D018696:Neuroprotective Agents / Q000494:pharmacology*; D052247:Nitric Oxide Synthase Type II / Q000378:metabolism; D011758:Pyrroles / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013481:Superoxides / Q000032:analysis / Q000037:antagonists & inhibitors*; D013997:Time Factors
chemical_list: D006538:Heptanoic Acids; D018696:Neuroprotective Agents; D011758:Pyrroles; D013481:Superoxides; D000069059:Atorvastatin; D052247:Nitric Oxide Synthase Type II; D019255:NADPH Oxidases